Leigh A Peterson1, Lawrence J Cheskin2, Michael A Schweitzer3, Thomas H Magnuson3, Kimberley E Steele3. 1. The Johns Hopkins Center for Bariatric Surgery, The Johns Hopkins Bloomberg School of Public Health, 4940 Eastern Avenue, Baltimore, MD, 21224, USA. leighpeterson@jhmi.edu. 2. The Johns Hopkins Weight Management Center, The Global Obesity Prevention Center at Johns Hopkins, The Johns Hopkins Bloomberg School of Public Health, 550 N Broadway, Baltimore, MD, 21205, USA. 3. The Johns Hopkins Center for Bariatric Surgery, 4940 Eastern Avenue, Baltimore, MD, 21224, USA.
Abstract
BACKGROUND: Since obesity increases vitamin D deficiency (VDD) risk, bariatric surgery candidates are high-risk. Previously, we documented 71.4% VDD at our center. OBJECTIVES: To investigate diagnosis and treatment for VDD in our bariatric candidates. METHODS: 25(OH)D, if pending, and supplementation (form, dosing, frequency) were prospectively documented in 265 candidates. RESULTS: Candidates were 83.0% female, 48.9% white, age 43 ± 13 years and BMI 46.3 ± 10.5 kg/m(2). 25(OH)D was available for 18.5%: 35.7% VDD 39.3% insufficiency. VDD history did not differ by demographics or procedure, as with those tested versus not. CONCLUSION: VDD testing was lower than clinically-indicated. Of those tested, 35.7% were deficient and 39.3% insufficient. We previously reported higher rates: 71.4% deficiency, 92.9% insufficiency. Thus, many candidates are untested but high-risk.
BACKGROUND: Since obesity increases vitamin D deficiency (VDD) risk, bariatric surgery candidates are high-risk. Previously, we documented 71.4% VDD at our center. OBJECTIVES: To investigate diagnosis and treatment for VDD in our bariatric candidates. METHODS: 25(OH)D, if pending, and supplementation (form, dosing, frequency) were prospectively documented in 265 candidates. RESULTS: Candidates were 83.0% female, 48.9% white, age 43 ± 13 years and BMI 46.3 ± 10.5 kg/m(2). 25(OH)D was available for 18.5%: 35.7% VDD 39.3% insufficiency. VDD history did not differ by demographics or procedure, as with those tested versus not. CONCLUSION: VDD testing was lower than clinically-indicated. Of those tested, 35.7% were deficient and 39.3% insufficient. We previously reported higher rates: 71.4% deficiency, 92.9% insufficiency. Thus, many candidates are untested but high-risk.
Authors: Leigh A Peterson; Lawrence J Cheskin; Margaret Furtado; Konstantinos Papas; Michael A Schweitzer; Thomas H Magnuson; Kimberley E Steele Journal: Obes Surg Date: 2016-04 Impact factor: 4.129
Authors: Michael F Holick; Neil C Binkley; Heike A Bischoff-Ferrari; Catherine M Gordon; David A Hanley; Robert P Heaney; M Hassan Murad; Connie M Weaver Journal: J Clin Endocrinol Metab Date: 2011-06-06 Impact factor: 5.958
Authors: Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal Journal: JAMA Date: 2006-04-05 Impact factor: 56.272
Authors: A Catharine Ross; JoAnn E Manson; Steven A Abrams; John F Aloia; Patsy M Brannon; Steven K Clinton; Ramon A Durazo-Arvizu; J Christopher Gallagher; Richard L Gallo; Glenville Jones; Christopher S Kovacs; Susan T Mayne; Clifford J Rosen; Sue A Shapses Journal: J Clin Endocrinol Metab Date: 2010-11-29 Impact factor: 5.958
Authors: Gary Whitlock; Sarah Lewington; Paul Sherliker; Robert Clarke; Jonathan Emberson; Jim Halsey; Nawab Qizilbash; Rory Collins; Richard Peto Journal: Lancet Date: 2009-03-18 Impact factor: 79.321
Authors: Mary O'Kane; Helen M Parretti; Jonathan Pinkney; Richard Welbourn; Carly A Hughes; Jessica Mok; Nerissa Walker; Denise Thomas; Jennifer Devin; Karen D Coulman; Gail Pinnock; Rachel L Batterham; Kamal K Mahawar; Manisha Sharma; Alex I Blakemore; Iris McMillan; Julian H Barth Journal: Obes Rev Date: 2020-08-02 Impact factor: 9.213